CD20-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MRG001 / Lepu Med
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting
1
108
RoW
MRG001
Shanghai Miracogen Inc.
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
10/22
10/23
TRS005 / Zhejiang Teruisi Biopharma
NCT06886139: A Phase 2 Study of TRS005 in Patients with CD20-positive R/R DLBCL.

Not yet recruiting
2
139
RoW
TRS005
Zhejiang Teruisi Pharmaceutical Inc.
CD20-positive Diffuse Large B-Cell Lymphoma
01/27
09/27
ChiCTR1900025308: A multicenter, single-arm, dose-escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of TRS005 in patients with relapsed or refractory CD20-positive B-cell Non-Hodgkin's lymphoma treated with single and multiple doses

Recruiting
1
30
 
5mg/m2 ;20 mg/m2 ;10 mg/m2 ;30 mg/m2 ;40 mg/m2 ;50 mg/m2
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, External funding
relapsed or refractory CD20-positive B-cell Non-Hodgkin's lymphoma
 
 
TRS00501001, NCT05395533: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Recruiting
1
152
RoW
Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005
Zhejiang Teruisi Pharmaceutical Inc.
CD20-positive B-cell Non-Hodgkin Lymphoma
12/23
12/24
nab-paclitaxel/rituximab nanoparticle (AR160) / Sorrento
No trials found
EDC9 / Centrose
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MRG001 / Lepu Med
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting
1
108
RoW
MRG001
Shanghai Miracogen Inc.
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
10/22
10/23
TRS005 / Zhejiang Teruisi Biopharma
NCT06886139: A Phase 2 Study of TRS005 in Patients with CD20-positive R/R DLBCL.

Not yet recruiting
2
139
RoW
TRS005
Zhejiang Teruisi Pharmaceutical Inc.
CD20-positive Diffuse Large B-Cell Lymphoma
01/27
09/27
ChiCTR1900025308: A multicenter, single-arm, dose-escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of TRS005 in patients with relapsed or refractory CD20-positive B-cell Non-Hodgkin's lymphoma treated with single and multiple doses

Recruiting
1
30
 
5mg/m2 ;20 mg/m2 ;10 mg/m2 ;30 mg/m2 ;40 mg/m2 ;50 mg/m2
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, External funding
relapsed or refractory CD20-positive B-cell Non-Hodgkin's lymphoma
 
 
TRS00501001, NCT05395533: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Recruiting
1
152
RoW
Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005
Zhejiang Teruisi Pharmaceutical Inc.
CD20-positive B-cell Non-Hodgkin Lymphoma
12/23
12/24
nab-paclitaxel/rituximab nanoparticle (AR160) / Sorrento
No trials found
EDC9 / Centrose
No trials found

Download Options